Dovitinib
- Generic Name
- Dovitinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21FN6O
- CAS Number
- 405169-16-6
- Unique Ingredient Identifier
- I35H55G906
- Background
Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with different cancers, including acute myeloid leukemia (AML) and multiple myeloma. Chiron currently has three ongoing Phase I...
- Indication
Investigated for use/treatment in multiple myeloma and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2018-03-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT02116803
- Locations
- πͺπΈ
Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain
A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2015-01-19
- Lead Sponsor
- Oscar Goodman, Jr.
- Registration Number
- NCT02065323
- Locations
- πΊπΈ
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
- Conditions
- Interventions
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT01994590
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma
- First Posted Date
- 2013-10-30
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- PD Dr. Martin Glas
- Target Recruit Count
- 12
- Registration Number
- NCT01972750
- Locations
- π©πͺ
Department of Neurology and Center of Integrated Oncology, University Hospital Bonn, Bonn, Germany
An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 40
- Registration Number
- NCT01964144
- Locations
- π°π·
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of
Maintenance Dovitinib for Colorectal and Pancreas Cancer
- First Posted Date
- 2013-06-28
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 9
- Registration Number
- NCT01888965
- Locations
- πΊπΈ
Georgetown University- Lombardi Cancer Center, Washington, District of Columbia, United States
Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2013-05-23
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT01861197
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2015-02-03
- Lead Sponsor
- Auckland District Health Board
- Target Recruit Count
- 30
- Registration Number
- NCT01791387
- Locations
- π³πΏ
Auckland Hospital, Auckland, New Zealand
A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy
- First Posted Date
- 2013-01-16
- Last Posted Date
- 2015-09-17
- Lead Sponsor
- Ontario Clinical Oncology Group (OCOG)
- Target Recruit Count
- 12
- Registration Number
- NCT01769547
- Locations
- π¨π¦
Northeast Cancer Centre, Health Sciences North, Sudbury, Ontario, Canada
π¨π¦Tom Baker Cancer Centre, Calgary, Alberta, Canada
π¨π¦Juravinski Cancer Centre, Hamilton, Ontario, Canada
Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2012-12-20
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- Manmeet Ahluwalia, MD
- Target Recruit Count
- 33
- Registration Number
- NCT01753713
- Locations
- πΊπΈ
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.